stockrow
Friday 6 November 2026
Export MMED’s income statement to Excel — free account
MiniMed Group, Inc.
MMED Healthcare Medical Instruments & Supplies
MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
18.23
1.06
−5.50%
Follow MMED
Alert me
| Older periods | Jul '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+3 more quarters Free account |
0.00 | 0.00 | — | 0.00 |
P/S ratio |
0.00 | 0.00 | — | 1.67 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(173.13) | (173.13) | — | (103.51) | |
P/B ratio |
1.35 | 1.35 | — | 1.40 | |
Price to Tangible BV |
4.27 | 4.27 | — | 4.01 | |
EV/Sales |
0.00 | 0.00 | — | 1.60 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(166.59) | (166.59) | — | (36.31) | |
EV/FCF |
(10.58) | (10.58) | — | (10.76) | |
Quick Ratio |
— | 0.95 | 0.71 | 0.49 | |
Current Ratio |
— | 1.59 | 1.92 | 1.81 | |
Net Debt/EBITDA |
0.00 | 0.10 | 0.00 | (4.60) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | 0.00 | 0.00 | 1.29 | |
Operating CF/Net income |
7.42 | 0.23 | — | 0.00 | |
Capex/Depreciation |
(1.36) | (1.43) | — | (1.00) | |
Research and Development Expense of Revenue |
17.29% | 14.43% | — | 13.64% | |
Selling, General and Administrative Expense of Revenue |
39.14% | 39.11% | — | 37.01% | |
Intangible Assets out of Total Assets |
0.00 | 0.55 | 0.51 | 0.50 | |
Share Based Compensation of Revenue |
1.24% | 4.81% | — | 1.19% | |
Graham Net Nets |
0.05 | 0.05 | — | 0.06 | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(3.27%) | (3.27%) | — | (3.27%) | |
Free Cash Flow Yield |
(9.43%) | (9.43%) | — | (8.91%) | |
Revenue per Share |
2.86 | 3.12 | — | 3.00 | |
Operating CF per Share |
(0.56) | (0.11) | — | (0.17) | |
Capex per Share |
(0.21) | (0.66) | — | (0.15) | |
Free Cash Flow per Share |
(0.77) | (0.77) | — | (0.32) | |
Cash per Share |
0.00 | 0.04 | 0.00 | 0.74 | |
Shareholders Equity per Share |
0.00 | 13.69 | 0.00 | 12.88 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
0.00 | 13.69 | 0.00 | 12.88 | |
Free Cash Flow |
(194.00) | (194.00) | — | (90.00) | |
Working Capital |
— | 412.00 | 646.00 | 635.00 | |
Capital Expenditures |
(53.00) | (167.00) | — | (41.00) | |
Net Current Asset Value |
0.00 | 227.00 | 329.00 | 319.00 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.07 | 0.21 | — | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Assets |
— | 2,171.50 | 2,315.00 | 2,359.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026